These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

364 related articles for article (PubMed ID: 25879376)

  • 1. Non-total body irradiation myeloablative conditioning with intravenous busulfan and cyclophosphamide in hematopoietic stem cell transplantation for malignant infantile osteopetrosis.
    Behfar M; Dehghani SS; Hosseini AS; Jalali A; Hamidieh AA; Ghavamzadeh A
    Pediatr Transplant; 2015 Jun; 19(4):422-7. PubMed ID: 25879376
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.
    Güngör T; Teira P; Slatter M; Stussi G; Stepensky P; Moshous D; Vermont C; Ahmad I; Shaw PJ; Telles da Cunha JM; Schlegel PG; Hough R; Fasth A; Kentouche K; Gruhn B; Fernandes JF; Lachance S; Bredius R; Resnick IB; Belohradsky BH; Gennery A; Fischer A; Gaspar HB; Schanz U; Seger R; Rentsch K; Veys P; Haddad E; Albert MH; Hassan M;
    Lancet; 2014 Feb; 383(9915):436-48. PubMed ID: 24161820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Allogeneic stem cell transplantation for 8 patients with malignant infantile osteopetrosis in China].
    Zhu GH; Qin MQ; Wang B; Zhou X; Yang J; Jia CG; Wu Y; Wang XS; Wu MY
    Zhonghua Er Ke Za Zhi; 2012 Nov; 50(11):807-12. PubMed ID: 23302608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of allogeneic Hematopoietic Stem Cell Transplantation on Diamond-Blackfan anemia using busulfan-based myeloablative regimen.
    Behfar M; Koochakzadeh L; Yazdanian N; Salajegheh P; Rostami T; Khodayari-Namini N; Ghavamzadeh A; Hamidieh AA
    Turk J Pediatr; 2019; 61(3):407-412. PubMed ID: 31916719
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic stem cell transplantation using myeloablative and reduced-intensity conditioning in patients with major histocompatibility complex class II deficiency.
    Al-Mousa H; Al-Shammari Z; Al-Ghonaium A; Al-Dhekri H; Al-Muhsen S; Al-Saud B; Arnaout R; Al-Seraihy A; Al-Jefri A; Al-Ahmari A; Ayas M; El-Solh H
    Biol Blood Marrow Transplant; 2010 Jun; 16(6):818-23. PubMed ID: 20079864
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A modified myeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation, consisting of intravenous busulfan, cyclophosphamide and total lymphoid irradiation, in advanced leukemia].
    Nakamae H; Terada Y; Nakane T; Koh H; Nakamae M; Aimoto R; Hirose A; Hayashi Y; Nishimoto M; Inoue E; Yoshimura T; Inoue A; Koh KR; Yamane T; Hino M
    Gan To Kagaku Ryoho; 2010 Sep; 37(9):1691-5. PubMed ID: 20841930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard versus alternative myeloablative conditioning regimens in allogeneic hematopoietic stem cell transplantation for high-risk acute leukemia.
    Mengarelli A; Iori A; Guglielmi C; Romano A; Cerretti R; Torromeo C; Micozzi A; Fenu S; Laurenti L; Donato V; De Felice L; Arcese W
    Haematologica; 2002 Jan; 87(1):52-8. PubMed ID: 11801465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Post-transplantation Cyclophosphamide and Sirolimus after Haploidentical Hematopoietic Stem Cell Transplantation Using a Treosulfan-based Myeloablative Conditioning and Peripheral Blood Stem Cells.
    Cieri N; Greco R; Crucitti L; Morelli M; Giglio F; Levati G; Assanelli A; Carrabba MG; Bellio L; Milani R; Lorentino F; Stanghellini MT; De Freitas T; Marktel S; Bernardi M; Corti C; Vago L; Bonini C; Ciceri F; Peccatori J
    Biol Blood Marrow Transplant; 2015 Aug; 21(8):1506-14. PubMed ID: 26001696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML.
    Horn B; Baxter-Lowe LA; Englert L; McMillan A; Quinn M; Desantes K; Cowan M
    Bone Marrow Transplant; 2006 Feb; 37(3):263-9. PubMed ID: 16327813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-total body irradiation myeloablative conditioning with intravenous busulfan and cyclophosphamide is feasible in bone marrow transplantation for osteopetrosis.
    Naithani R
    Pediatr Transplant; 2015 Nov; 19(7):801-2. PubMed ID: 26179773
    [No Abstract]   [Full Text] [Related]  

  • 11. Modified conditioning regimen busulfan-cyclophosphamide followed by allogeneic stem cell transplantation in patients with multiple myeloma.
    Zhang XH; Huang XJ; Liu KY; Xu LP; Liu DH; Chen H; Chen YH; Wang JZ; Han W; Lu DP
    Chin Med J (Engl); 2007 Mar; 120(6):463-8. PubMed ID: 17439737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A fludarabine-based dose-reduced conditioning regimen followed by allogeneic stem cell transplantation from related or unrelated donors in patients with myelodysplastic syndrome.
    Kröger N; Schetelig J; Zabelina T; Krüger W; Renges H; Stute N; Schrum J; Kabisch H; Siegert W; Zander AR
    Bone Marrow Transplant; 2001 Oct; 28(7):643-7. PubMed ID: 11704786
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [The clinical characteristics of adult hemophagocytic lymphohistiocytosis treated with haploidentical donor hematopoietic stem cell transplantation].
    Fu L; Wei N; Wang JS; Wu L; Wang YN; Huang DY; Liu JL; Wang Z
    Zhonghua Nei Ke Za Zhi; 2017 Apr; 56(4):273-278. PubMed ID: 28355720
    [No Abstract]   [Full Text] [Related]  

  • 14. Reduced toxicity, myeloablative HLA-haploidentical hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for sickle cell disease.
    Wiebking V; Hütker S; Schmid I; Immler S; Feuchtinger T; Albert MH
    Ann Hematol; 2017 Aug; 96(8):1373-1377. PubMed ID: 28573314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning.
    Raiola AM; Dominietto A; Ghiso A; Di Grazia C; Lamparelli T; Gualandi F; Bregante S; Van Lint MT; Geroldi S; Luchetti S; Ballerini F; Miglino M; Varaldo R; Bacigalupo A
    Biol Blood Marrow Transplant; 2013 Jan; 19(1):117-22. PubMed ID: 22940057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful unrelated mismatched cord blood transplantation in a child with malignant infantile osteopetrosis.
    Jaing TH; Hou JW; Chen SH; Huang IA; Wang CJ; Lee WI
    Pediatr Transplant; 2006 Aug; 10(5):629-31. PubMed ID: 16857002
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Engraftment and survival following hematopoietic stem cell transplantation for osteopetrosis using a reduced intensity conditioning regimen.
    Tolar J; Bonfim C; Grewal S; Orchard P
    Bone Marrow Transplant; 2006 Dec; 38(12):783-7. PubMed ID: 17086207
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of total body irradiation vs busulfan in combination with cyclophosphamide as conditioning for unrelated stem cell transplantation in CML patients.
    Kröger N; Zabelina T; Krüger W; Renges H; Stute N; Kabisch H; Jaburg N; Löliger C; Krüll A; Zander AR
    Bone Marrow Transplant; 2001 Feb; 27(4):349-54. PubMed ID: 11313663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A well-tolerated regimen of 800 cGy TBI-fludarabine-busulfan-ATG for reliable engraftment after unmanipulated haploidentical peripheral blood stem cell transplantation in adult patients with acute myeloid leukemia.
    Yahng SA; Kim JH; Jeon YW; Yoon JH; Shin SH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS; Park CW; Kim HJ
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):119-29. PubMed ID: 25300871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Favorable outcome of hematopoietic stem cell transplantation using a targeted once-daily intravenous busulfan-fludarabine-etoposide regimen in pediatric and infant acute lymphoblastic leukemia patients.
    Lee JW; Kang HJ; Kim S; Lee SH; Yu KS; Kim NH; Jang MK; Kim H; Song SH; Park JD; Park KD; Shin HY; Jang IJ; Ahn HS
    Biol Blood Marrow Transplant; 2015 Jan; 21(1):190-5. PubMed ID: 25255163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.